

The PrenatalSEQ Test can detect the most common chromosomal conditions, giving you early insights into your baby’s health:
Trisomy 21 (Down syndrome): the most common trisomy at birth, associated with intellectual disabilities and sometimes heart or digestive conditions. Many people with Down syndrome live well into adulthood.
Trisomy 18 (Edwards syndrome): a rare condition often associated with miscarriage and severe medical complications. Most affected babies do not survive beyond the first year of life.
Trisomy 13 (Patau syndrome): another rare condition, linked to multiple birth defects and high rates of miscarriage, with most affected babies not surviving beyond infancy.
Sex chromosome conditions (optional): these occur when there is a missing, extra, or altered X or Y chromosome. They include Turner syndrome (X), Klinefelter syndrome (XXY), Triple X (XXX), and XYY.
Fetal sex determination (optional, no additional cost).

No. The PrenatalSEQ Test is completely non-invasive — it only requires a simple blood sample from the mother.
Unlike invasive procedures such as amniocentesis or chorionic villus sampling (CVS), PrenatalSEQ carries no risk of miscarriage or harm to your pregnancy.
It’s a safe and reliable way to gain early insights into your baby’s health.
NIPT, including PrenatalSEQ, is more accurate than traditional first-trimester screening methods (ultrasound and maternal serum testing) for detecting trisomy 21, 18, and 13. This means fewer false-positive and false-negative results, giving you greater confidence in your results.
It’s important to remember that NIPT is a screening test, not a diagnostic test. In rare cases, differences between the DNA from the placenta and the fetus can affect results.
If a high-risk result is reported, your doctor may recommend follow-up diagnostic testing — such as chorionic villus sampling (CVS) or amniocentesis — to confirm whether your baby is affected.

The PrenatalSEQ Test can be ordered by a healthcare professional for women who are at least 10 weeks pregnant.
It is suitable for:
Singleton pregnancies
Twin pregnancies (conceived naturally or by IVF, with your own egg or a donor egg)
Important notes for twin pregnancies:
PrenatalSEQ can determine fetal sex but not sex chromosome conditions.
Results will be reported as one combined outcome:
If male → one or both twins are male
If female → both twins are female
PrenatalSEQ is not suitable if there is a vanishing twin.
What PrenatalSEQ does not assess:
Mosaicism
Partial trisomies
Translocations

Like all NIPT methods, the PrenatalSEQ Test has certain limitations. It is important to remember that NIPT is a screening test, not a diagnostic test.
Not suitable for:
Pregnancies with more than two fetuses
Cases of vanishing twin or fetal demise
Mosaicism, partial trisomies, triploidy, or translocations
Maternal conditions such as aneuploidy, transplant, or malignancy
PrenatalSEQ also does not detect neural tube defects.
Special notes for twin pregnancies:
A high-probability result applies to at least one fetus
A male result means one or both twins are male
A female result means both twins are female
Accuracy considerations:
A low-probability result does not guarantee that a baby is unaffected
Rarely, a baby without a condition may receive a high-probability result
In cases of high-probability results — or if there are other clinical indications — confirmatory testing (such as CVS or amniocentesis) is required for a diagnosis
Results from the PrenatalSEQ Test are usually available within 5-7 working days (from the time your sample is received at the laboratory).
You will still have your routine 12-week ultrasound scan, where your doctor can examine your baby’s anatomy in detail — including measurements such as nuchal translucency and nasal bone, along with other important checks.
At this visit, your healthcare provider can discuss both your DNA results and your ultrasound findings with you. Based on this information, you can decide together whether further testing, such as chorionic villus sampling (CVS) or amniocentesis, is necessary.


